Abstract
The hallmark of atopic asthma is transient airways hyperresponsiveness (AHR) preceded by aeroallergen-induced Th-cell activation. This is preceded by upregulation of CD86 on resident airway dendritic cells (DCs) that normally lack competence in T-cell triggering. Moreover, AHR duration is controlled via T-regulatory (Treg) cells, which can attenuate CD86 upregulation on DC. We show that airway mucosal Treg/DC interaction represents an accessible therapeutic target for asthma control. Notably, baseline airway Treg activity in sensitized rats can be boosted by microbe-derived stimulation of the gut, resulting in enhanced capacity to control CD86 expression on airway DC triggered by aeroallergen and accelerated resolution of AHR.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Asthma / immunology*
-
Asthma / microbiology
-
Asthma / therapy*
-
B7-2 Antigen / genetics
-
Bacteria / cytology
-
Bacteria / immunology*
-
Bacteria / metabolism
-
Bronchial Hyperreactivity / immunology
-
Bronchial Hyperreactivity / therapy
-
CD4-Positive T-Lymphocytes / immunology
-
Cell Extracts / immunology*
-
Cell Extracts / therapeutic use
-
Cytokines / immunology
-
Dendritic Cells / immunology
-
Disease Models, Animal
-
Forkhead Transcription Factors / metabolism
-
Gastrointestinal Tract / immunology*
-
Gastrointestinal Tract / microbiology
-
Interleukin-2 Receptor alpha Subunit / immunology
-
Rats
-
Respiratory System / immunology*
-
T-Lymphocytes, Helper-Inducer / immunology
-
T-Lymphocytes, Regulatory / immunology*
Substances
-
B7-2 Antigen
-
Broncho-Vaxom
-
Cell Extracts
-
Cytokines
-
Forkhead Transcription Factors
-
Foxp3 protein, rat
-
Interleukin-2 Receptor alpha Subunit